PURPOSE: The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features. METHODS: Tumor specimens from 126 patients were analyzed by immunohistochemistry and, in selected cases, by reverse transcriptase polymerase chain reaction (RT-PCR), and data were statistically analyzed by SPSS. RESULTS: The mean expression levels of tumor tissues in the case of P-gp and LRP did not exceed the one of normal epithelia, while MRP1 was significantly enhanced in NSCLC. A weak association was observed between higher grading and P-glycoprotein expression (p <0.08) as well as lower grading and MRP1 expression in the case of adenocarcinoma (p <0.05). MRP1 levels were highest in TNM stage I and declined with advanced stage (p <0.03). A significant association was found between high MRP1 levels and longer overall survival (N =115, p <0.04), which was highly significant in the patient group never treated with chemotherapy (N =77; p <0.007). P-gp expression was enhanced in those patients who had received chemotherapy before surgery (p <0.05). CONCLUSIONS: Our data point towards a major role of MRP1 in the intrinsic treatment resistance of NSCLC and suggest, in addition, a significant activation of P-gp expression during chemotherapy.
PURPOSE: The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features. METHODS:Tumor specimens from 126 patients were analyzed by immunohistochemistry and, in selected cases, by reverse transcriptase polymerase chain reaction (RT-PCR), and data were statistically analyzed by SPSS. RESULTS: The mean expression levels of tumor tissues in the case of P-gp and LRP did not exceed the one of normal epithelia, while MRP1 was significantly enhanced in NSCLC. A weak association was observed between higher grading and P-glycoprotein expression (p <0.08) as well as lower grading and MRP1 expression in the case of adenocarcinoma (p <0.05). MRP1 levels were highest in TNM stage I and declined with advanced stage (p <0.03). A significant association was found between high MRP1 levels and longer overall survival (N =115, p <0.04), which was highly significant in the patient group never treated with chemotherapy (N =77; p <0.007). P-gp expression was enhanced in those patients who had received chemotherapy before surgery (p <0.05). CONCLUSIONS: Our data point towards a major role of MRP1 in the intrinsic treatment resistance of NSCLC and suggest, in addition, a significant activation of P-gp expression during chemotherapy.
Authors: F Narasaki; M Oka; M Fukuda; R Nakano; K Ikeda; H Takatani; K Terashi; H Soda; O Yano; T Nakamura; L A Doyle; T Tsuruo; S Kohno Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: K Nooter; F T Bosman; H Burger; K E van Wingerden; M J Flens; R J Scheper; R G Oostrum; A W Boersma; A van der Gaast; G Stoter Journal: Ann Oncol Date: 1996-01 Impact factor: 32.976
Authors: G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper Journal: Nat Med Date: 1995-06 Impact factor: 53.440
Authors: S R Wright; A H Boag; G Valdimarsson; D R Hipfner; B G Campling; S P Cole; R G Deeley Journal: Clin Cancer Res Date: 1998-09 Impact factor: 12.531
Authors: E Ota; Y Abe; Y Oshika; Y Ozeki; M Iwasaki; H Inoue; H Yamazaki; Y Ueyama; K Takagi; T Ogata Journal: Br J Cancer Date: 1995-09 Impact factor: 7.640
Authors: Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman Journal: Drug Resist Updat Date: 2012-04-06 Impact factor: 18.500
Authors: G Sonvilla; S Allerstorfer; C Heinzle; S Stättner; J Karner; M Klimpfinger; F Wrba; H Fischer; C Gauglhofer; S Spiegl-Kreinecker; B Grasl-Kraupp; K Holzmann; M Grusch; W Berger; B Marian Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640